Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.1%

24 terminated/withdrawn out of 583 trials

Success Rate

93.0%

+6.5% vs industry average

Late-Stage Pipeline

7%

43 trials in Phase 3/4

Results Transparency

4%

12 of 321 completed trials have results

Key Signals

88 recruiting12 with results20 terminated4 withdrawn

Enrollment Performance

Analytics

N/A
300(73.3%)
Phase 2
34(8.3%)
Phase 1
30(7.3%)
Phase 4
29(7.1%)
Phase 3
14(3.4%)
Early Phase 1
2(0.5%)
409Total
N/A(300)
Phase 2(34)
Phase 1(30)
Phase 4(29)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (583)

Showing 20 of 583 trials
NCT05764746Phase 2Completed

Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial

Role: collaborator

NCT07721870Not ApplicableCompleted

Feasibility, Acceptability and Preliminary Clinical Outcome Signals Following a Digital Things You Do (TYD) Intervention in Primary Care: A Single-case Study

Role: lead

NCT07706816Not ApplicableNot Yet Recruiting

Evaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study

Role: lead

NCT07003906Not ApplicableRecruiting

Treating Emergency Laparotomy Incisions With Negative Pressure Wound Therapy

Role: lead

NCT05376644Not ApplicableCompleted

Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3

Role: collaborator

NCT04292626Phase 1Completed

Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose

Role: collaborator

NCT05940298Phase 1Completed

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8

Role: collaborator

NCT07569549Not ApplicableRecruiting

Surgery for Thumb Base Osteoarthritis: Joint Replacement vs. Trapeziectomy

Role: lead

NCT07292571Phase 2Enrolling By Invitation

Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107

Role: collaborator

NCT04288518Phase 1Completed

Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.

Role: collaborator

NCT04277338Phase 1Completed

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3

Role: collaborator

NCT05412446Phase 2Completed

99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

Role: collaborator

NCT06101927Phase 1Completed

Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413

Role: collaborator

NCT03991260Completed

99mTc-ADAPT6-based HER2 Imaging in Breast Cancer

Role: collaborator

NCT05695859Completed

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

Role: collaborator

NCT04746638Phase 1Completed

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26

Role: collaborator

NCT05412459Completed

99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

Role: collaborator

NCT06386653Phase 1Completed

Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1

Role: collaborator

NCT05620472Phase 1Completed

Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1

Role: collaborator

NCT07275463Phase 2Enrolling By Invitation

[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression

Role: collaborator